Boston Scientific Completes $540M Acquisition of SoniVie to Expand RDN Portfolio

May 07, 2025 22:16 CST Updated 22:16

SoniVie

Medical Device Developer

Boston Scientific

Medical Device Manufacturer

Boston Scientific Corporation Announces Completion of Acquisition of RDN Company---SoniVie acquisition, officially returning to the RDN family. The acquisition cost is as high as 600 million US dollars (of which 400 million US dollars is prepaid and 200 million US dollars is milestone bonus). However, before the acquisition, Boston Scientific heldSoniVie 10%Therefore, Boston Scientific will ultimately only need to pay 540 million US dollars.

Boston Scientific Evaluation

"We have completed the acquisition of SoniVie and will integrate the innovative renal denervation technology into our interventional cardiology portfolio. Welcome to the SoniVie team, and we look forward to jointly advancing the innovation in hypertension treatment."

In the past year, Boston Scientific has been accelerating its layout in the cardiovascular field, from peripheral to coronary to hypertension.

September 2024: Completed the acquisition of Silk Road Medical for $1.18 billion
January 2025: Announcement of the acquisition of Bolt Medical, entering the Intravascular Lithotripsy (IVL) field
May 2025:$540 Million to Complete AcquisitionSoniVie

These are all high-growth areas,From 2023 to 2028,RDN and IVLThe market's compound annual growth rate will reach 22.0%.23.6%. These acquisitions will enable Boston Scientific to maintain its current high growth rate over the next five years, with Q1 sales growth this year.20.9% (The main driving force behind the growth comes fromCardiovascular Business 26.2%, with PFA as the Biggest Contributor）。

Boston Scientific gains not only the RDN product through this acquisition but also two additional products: pulmonary artery hypertension denervation and chronic obstructive pulmonary disease with chronic bronchitis denervation.

TIVUS

TIVUS(Therapeutic Intravascular Ultrasound) isA catheter-based endovascular technique for renal and bronchial arteriesPeripheral Sympathetic Nerves。

TIVUSTheThe distal end of the catheter can generate non-focused ultrasound waves, which can penetrate through flowing blood and arterial walls. The energy on the vascular wall is absorbed by the tissue outside the vessel (especially nerve bundles), leading to nerve heating and subsequent sympathetic nerve death.Sympathetic NerveLose its ability to transmit signals. This leads to a reduction in sympathetic hormones released from nerves. The decrease in these hormones can cause blood vessels to relax, reducing vascular resistance and lowering vascular pressure.

TIVUS Demonstration

SoniVie

SoniVieIn 2014 by Accelled Ventures in IsraelList established,Is a developmentTIVUSMedical device companies,TIVUSIs the only ultrasound denervation platform with active development programs in three therapeutic areas: pulmonary artery hypertension denervation, renal artery denervation for resistant hypertension, and denervation for chronic obstructive pulmonary disease with chronic bronchitis. These conditions affect millions of patients in the United States and Europe.